CN110225926B - 抗Tau纳米抗体 - Google Patents

抗Tau纳米抗体 Download PDF

Info

Publication number
CN110225926B
CN110225926B CN201780080870.6A CN201780080870A CN110225926B CN 110225926 B CN110225926 B CN 110225926B CN 201780080870 A CN201780080870 A CN 201780080870A CN 110225926 B CN110225926 B CN 110225926B
Authority
CN
China
Prior art keywords
gly
ser
nanobody
lys
tau
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780080870.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN110225926A (zh
Inventor
丹尼尔·法格雷
玛塞勒·穆兰
卡特琳·盖齐
帕斯卡莱·佩雷特
萨比娜·谢里西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
French National Institute Of Health And Medicine
Grenoble university central hospital
Universite Joseph Fourier Grenoble 1
Original Assignee
French National Institute Of Health And Medicine
Grenoble university central hospital
Universite Joseph Fourier Grenoble 1
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by French National Institute Of Health And Medicine, Grenoble university central hospital, Universite Joseph Fourier Grenoble 1 filed Critical French National Institute Of Health And Medicine
Publication of CN110225926A publication Critical patent/CN110225926A/zh
Application granted granted Critical
Publication of CN110225926B publication Critical patent/CN110225926B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201780080870.6A 2016-10-27 2017-10-27 抗Tau纳米抗体 Active CN110225926B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1660450A FR3058143B1 (fr) 2016-10-27 2016-10-27 Nanocorps anti-tau
FR1660450 2016-10-27
PCT/EP2017/077691 WO2018078140A1 (fr) 2016-10-27 2017-10-27 Nanocorps anti-tau

Publications (2)

Publication Number Publication Date
CN110225926A CN110225926A (zh) 2019-09-10
CN110225926B true CN110225926B (zh) 2024-05-03

Family

ID=58314353

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780080870.6A Active CN110225926B (zh) 2016-10-27 2017-10-27 抗Tau纳米抗体

Country Status (7)

Country Link
US (1) US10590191B2 (enExample)
EP (1) EP3532495A1 (enExample)
JP (1) JP7197494B2 (enExample)
CN (1) CN110225926B (enExample)
CA (1) CA3041066A1 (enExample)
FR (1) FR3058143B1 (enExample)
WO (1) WO2018078140A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190134997A (ko) 2017-02-17 2019-12-05 데날리 테라퓨틱스 인크. 항-tau 항체 및 이의 사용 방법
CN112649615A (zh) * 2020-12-21 2021-04-13 大连理工大学 一种检测不同大小的可溶性Aβ寡聚体的方法及应用
FR3134390B1 (fr) 2022-04-11 2025-10-24 Univ Grenoble Alpes Peptide utile pour le transport de molecules au travers de barrieres cellulaires

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104185640A (zh) * 2011-09-19 2014-12-03 阿克松神经系统科学公司 阿尔茨海默病中的tau蛋白介导病变的基于蛋白质的疗法和诊断
CN105339002A (zh) * 2013-06-10 2016-02-17 伊皮埃里安股份有限公司 治疗tau病变的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
AU6248994A (en) 1993-02-22 1994-09-14 Rockefeller University, The Production of high titer helper-free retroviruses by transient transfection
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
AU701643B2 (en) 1994-09-12 1999-02-04 Schering Aktiengesellschaft Process for manufacture of a modified collagen-induced platelet aggregation inhibitor pallidipin
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
WO2011026031A1 (en) 2009-08-28 2011-03-03 The Board Of Regents Of The University Of Texas System Antibodies that bind tau oligomers
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
WO2014059442A2 (en) 2012-10-12 2014-04-17 Arizona Board Agents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
EP2899208A1 (en) * 2014-01-28 2015-07-29 F.Hoffmann-La Roche Ag Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104185640A (zh) * 2011-09-19 2014-12-03 阿克松神经系统科学公司 阿尔茨海默病中的tau蛋白介导病变的基于蛋白质的疗法和诊断
CN105339002A (zh) * 2013-06-10 2016-02-17 伊皮埃里安股份有限公司 治疗tau病变的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Specific Targeting of Tau Oligomers in Htau Mice Prevents Cognitive Impairment and Tau Toxicity Following Injection with Brain-Derived Tau Oligomeric Seeds;Diana L. Castillo-Carranza等;《Journal of Alzheimer’s Disease》;20140517;S97-S111 *

Also Published As

Publication number Publication date
CN110225926A (zh) 2019-09-10
FR3058143A1 (fr) 2018-05-04
US10590191B2 (en) 2020-03-17
JP2020505056A (ja) 2020-02-20
CA3041066A1 (fr) 2018-05-03
JP7197494B2 (ja) 2022-12-27
WO2018078140A1 (fr) 2018-05-03
US20190263898A1 (en) 2019-08-29
FR3058143B1 (fr) 2021-03-12
EP3532495A1 (fr) 2019-09-04

Similar Documents

Publication Publication Date Title
US11739140B2 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
JP6290212B2 (ja) タウオパチーの処置方法
TWI551607B (zh) 人類化抗體
JP6446443B2 (ja) タウオパチーの処置方法
AU2017264975A1 (en) Anti-PHF-tau antibodies and their uses
TW201900682A (zh) 抗ｐｈｆ－ｔａｕ抗體及其用途
BRPI0709050B1 (pt) anticorpo ou fragmento do mesmo, composição, métodos para detectar protofibrilas ab in vitro, e, uso do anticorpo
KR20100097651A (ko) 베타-아밀로이드 펩티드에 특이적인 신규 항체 및 진단제 또는 진단약으로서의 그 용도
US9771423B2 (en) Anti-VCAM-1 nanobodies
US20230151083A1 (en) Anti-phf-tau antibodies and uses thereof
TW202115116A (zh) 抗EphA4抗體
US20240059766A1 (en) Tau binding compounds
CN110225926B (zh) 抗Tau纳米抗体
US20250289874A1 (en) Antibody against p-tau 217 and use thereof
EP4314048A1 (en) Anti-tau antibodies and uses thereof
ES2356159T5 (es) Anticuerpos selectivos de protofibrillas mejorados y su uso
ES2711073T3 (es) Anticuerpos anti-alfa-sinucleína humanos

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220812

Address after: The French Saint Martin derre

Applicant after: UNIVERSITE JOSEPH FOURIER

Applicant after: Grenoble University Central Hospital

Applicant after: French National Institute of Health and Medicine

Address before: The French Saint Martin derre

Applicant before: UNIVERSITE GRENOBLE ALPES

Applicant before: Grenoble University Central Hospital

Applicant before: French National Institute of Health and Medicine

GR01 Patent grant
GR01 Patent grant